Trials / Completed
CompletedNCT07052734
Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients
A Multicenter Retrospective Analysis of the Miti-gene Recurrence Score in Early-Stage Invasive HR-Positive, HER2-Negative Breast Cancer in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,843 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Update and validate the performance of the 21-gene score in prognostic stratification for early-stage HR-positive, HER2-negative breast cancer in China.
Conditions
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
- First posted
- 2025-07-06
- Last updated
- 2025-07-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07052734. Inclusion in this directory is not an endorsement.